Shanghai-based Kangpu Biopharmaceuticals, Ltd has reportedly raised close to RMB 100 million (USD 13.8 million) in a Series B financing round. The round was led by V-Capital, with additional investments from Northern Light Venture Capital, Lapam Capital, Yijing Capital, Realharmony Capital, and Yinxinggu Capital. The proceeds from this funding will be utilized to accelerate Kangpu’s clinical development of molecular glue protein ubiquitination degradation products and to support early-stage pipeline research.
Investment in Next-Generation Molecular Glue Technologies
Kangpu Biopharma is known for its new-generation molecular glue protein ubiquitination and protein degradation technologies, including NeoMIDES, SelPDEiS, and X-SYNERGY. These innovative technologies aim to revolutionize the treatment of various diseases through targeted protein degradation.
Clinical Progress and Upcoming Studies
The company recently completed enrollment in a Phase IIa clinical study for its product candidate KPG-818, which targets systemic lupus erythematosus in the US. In addition, KPG-121 is anticipated to initiate a global multi-center Phase II/III regulatory study for metastatic castration-resistant prostate cancer in the US shortly. These developments highlight Kangpu Biopharma’s commitment to advancing novel therapies for unmet medical needs.-Fineline Info & Tech
